Liraglutide, another GLP-1 agonist requiring daily injection, results in increased insulin sensitivity, decreased DNL, reduced BMI and suppression of lipolysis in patients with NASH (268). The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.